Losartan improves erectile function through suppression of corporal apoptosis and oxidative stress in rats with cavernous nerve injury

Yi Wang*, Xiang-Hu Meng*, Qi-Jie Zhang, Ya-Min Wang, Chen Chen, Yi-Chun Wang, Xiang Zhou, Cheng-Jian Ji, Ning-Hong Song

This study aimed to investigate the functional and morphological changes in the corpus cavernosum after cavernous nerve (CN) injury or neurectomy and then reveal whether treatment with the angiotensin II Type 1 receptor antagonist losartan would improve erectile function as well as its potential mechanisms. A total of 48 10-week-old Sprague–Dawley male rats, weighing 300–350 g, were randomly divided into the following four groups ($n = 12$ per group): sham operation (Sham) group, bilateral cavernous nerve injury (BCNI) group, losartan-treated BCNI (BCNI + Losartan) group, and bilateral cavernous neurectomy (Neurectomy) group. Losartan was administered once daily by oral gavage at a dose of 30 mg kg$^{-1}$ day$^{-1}$ for 4 weeks starting on the day of surgery. The BCNI and the Neurectomy groups exhibited decreases in erectile response and increases in apoptosis and oxidative stress, compared with the Sham group. Treatment with losartan could have a modest effect on erectile function and significantly prevent corporal apoptosis and oxidative stress. The phospho-B-cell lymphoma 2 (Bcl-2)-associated death promoter (p-Bad)/Bad and phospho-the protein kinase B (p-AKT)/AKT ratios were substantially lower, while the Bcl-2-associated X protein (Bax)/Bcl-2 ratio, nuclear factor erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap-1), transforming growth factor-$eta$ 1 (TGF-$eta$1) and heme oxygenase-1 (HO-1) levels, and caspase-3 activity were higher in the BCNI and Neurectomy groups than in the Sham group. After 4 weeks of daily administration with losartan, these expression levels were remarkably attenuated compared with the BCNI group. Taken together, our results suggested that early administration of losartan after CN injury could slightly improve erectile function and significantly reduce corporal apoptosis and oxidative stress by inhibiting the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 pathways.

Keywords: angiotensin II; apoptosis; erectile dysfunction; fibrosis; losartan; oxidative stress

INTRODUCTION

Erectile dysfunction (ED), defined as the inability to attain or sustain erection satisfactory for sexual intercourse, has been predicted to affect 322 million individuals by the year 2025. Over 30 million men are diagnosed with ED every year, seriously diminishing their quality of life. Despite the application of robotic surgery and advances in nerve-sparing techniques, irreversible ED resulting from cavernous nerve (CN) injury remains an important quality of life issue after radical prostatectomy (RP). It has been reported that the rates of complete ED and partial erectile function after RP for clinically localized prostate cancer are 26%–100% and 16%–48%, respectively. Moreover, these patients are less responsive to phosphodiesterase Type 5 (PDE5) inhibitors, the first-line treatment for ED.

The pathophysiology of CN injury-induced ED remains poorly understood. Following CN injury caused by traction, compression, or use of electrocautery during RP, the damaged nerve will undergo Wallerian degeneration, leading to a temporary block of neurotransmission, which can result in morphological changes in the corpus cavernosum tissue, including cavernous fibrosis from increased collagen synthesis, a reduction in nitric oxide synthase-positive nerve density, and a decrease in smooth muscle and endothelial cells from apoptosis. Cavernous hypoxia, increased reactive oxygen species, and the upregulation of profibrotic factors such as transforming growth factor-$eta$ (TGF-$eta$) have also been implicated in the pathophysiology of ED.

Angiotensin II (Ang II), as the main active metabolite of the renin–angiotensin system, has been reported to cause endothelial dysfunction by increasing levels of reactive oxygen species and vasoconstrictive eicosanoids, which can counteract the effects of nitric oxide. Moreover, physiological amounts of Ang II and its receptors could be produced and identified in the corpus cavernosum. As demonstrated by Kifor et al., intracavernosal injection of Ang II could terminate erection in anesthetized dogs. In addition, Ang II activation might also be involved in apoptosis and fibrosis of the corpus cavernosum through Smad and non-Smad pathways, resulting in corporal veno-occlusive dysfunction (CVOD) and ED in diabetic rats. On the other hand, silencing of Ang II could alleviate ED via downregulating the Ras homolog...
family member A (RhoA)/Rho associated kinase (ROCK) signaling pathway in diabetic rats. Based on the functions of Ang II and its potential involvement in ED, we hypothesized that Ang II might also take part in apoptosis, oxidative stress, and fibrosis of the corpus cavernosum in rats with CN injury. Hence, the subsequent histologic changes in the corpus cavernosum tissue after CN injury were studied, and meanwhile, losartan, the Ang II Type 1 receptor antagonist, was utilized to examine whether daily administration of it would improve erectile function. The outcomes of these were anticipated to provide some references for future clinical management.

MATERIALS AND METHODS

Animals and experimental design

This study was conducted in strict accordance with the approved animal protocols and guidelines established by the Animal Care and Use Committee of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). All surgeries were performed under anesthesia, and all efforts were made to minimize the number and sufferings of experimental animals. A total of 48 10-week-old Sprague–Dawley male rats weighing 300–350 g were randomly divided into four groups (n = 12 per group): sham operation (Sham) group, bilateral cavernous nerve injury (BCNI) group, losartan-treated BCNI (BCNI+Losartan) group, and bilateral cavernous neurectomy (Neurectomy) group.

All rats were anesthetized with intraperitoneal injection of pentobarbital sodium (40 mg kg\(^{-1}\), P3761, Sigma-Aldrich, Copenhagen, Denmark) before surgery. The major pelvic ganglion (MPG) and the CNs were identified dorsolateral to the prostate by blunt dissection with the aid of a dissecting microscope (Zeiss, Göttingen, Germany). In the Sham group, rats underwent only MPG and CN exposure without further manipulation. In the BCNI group, the bilateral CNs were crushed using a nonserrated hemostat (Karl Storz Co., Tuttingen, Germany) about 2 mm distal to the ganglion for 2 min with full tip closure. In the neurectomy group, all rats underwent excision of a 2-mm section of the CN. In the BCNI + Losartan group, losartan was prepared by dissolving in distilled water and administered once daily by oral gavage at a dose of 30 mg kg\(^{-1}\) day\(^{-1}\) (MSD, Hangzhou, China) for 4 weeks starting from the day of surgery. The rats in the Sham, BCNI, and Neurectomy groups were given treatment with vehicle only (distilled water). Moreover, the individual performing the crush injury or neurectomy was blinded to treatment.

Erectile function evaluation

Four weeks postoperatively, erectile function was evaluated in anesthetized rats, and the bilateral MPGs and CNs were exposed with the abovementioned method. Intracavernosal pressure (ICP) and mean arterial pressure (MAP) were measured as described previously.\(^{19,20}\) For electrical stimulation of the CN, a bipolar hook electrode attached to a SDZ-II stimulator (Hwato, Suzhou, China) was placed around the injured or sham-treated CN proximal to the injury site. The stimulation parameters were 10 V at a frequency of 15 Hz with a square wave duration of 1.2 ms for 1 min. PowerLab/4SP (AD Instruments, Bella Vista, Australia) was used to acquire data during the experiment. The ratio of the maximal ICP to the corresponding MAP (ICP/MAP) was calculated and recorded.

At the end of the experiment, the corpus cavernosum, MPGs, and CNs were harvested. The midshaft of the penis was immediately fixed in 4% paraformaldehyde (Servicebio, Wuhan, China) overnight and then embedded in paraffin for histologic analysis. The MPGs and CNs were prefixed in 0.01 mol l\(^{-1}\) PBS (pH 7.3) containing 2.5% glutaraldehyde (Servicebio) for 2–4 h and then embedded in EMBed 812 (Servicebio) for transmission electron microscopy. The left cavernous tissue was rapidly frozen in liquid nitrogen and stored at −80°C until protein extraction.

Transmission electron microscopy (TEM)

For TEM analysis, fresh CNs were carefully isolated to avoid physical damage, with the size of the tissue sample no more than 1 mm\(^3\). The tissues were fixed in 0.01 mol l\(^{-1}\) PBS (pH 7.3) containing 2.5% glutaraldehyde for 2–4 h, washed in 0.1 mol l\(^{-1}\) PBS, postfixed with 1% osmium tetroxide (OsO4, Servicebio) in 0.1 mol l\(^{-1}\) PBS for 2 h at room temperature, and washed in 0.1 mol l\(^{-1}\) PBS. The tissue was then dehydrated in a graded ethanol series, treated with propylene oxide (Servicebio), embedded in EMBed 812, and cut into ultrathin sections (approximately 60–80 nm). The sections were subsequently stained with uranyl acetate (Servicebio) and lead citrate (Servicebio) and photographed on a Hitachi HT7700 transmission electron microscope (Hitachi, Tokyo, Japan).

Apoptotic cell detection

The TdT-mediated dUTP Nick-End Labeling (TUNEL) method was used to detect apoptosis with the ApopTag\(^\text{™}\) Red In Situ Apoptosis Detection Kit (Merck Millipore, Billerica, MA, USA), as previously described.\(^{21,22}\) Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). Under confocal microscopy (Nikon Corporation, Tokyo, Japan), five high-power (×400) fields were randomly selected, and the apoptotic index was calculated as the percentage of apoptotic cells among the total number of cells in the given area. Analysis was performed in a blinded fashion with the same standards in all groups. By covering the label on each slide, microscopic viewing, reading, and counting were performed blindly, and only thereafter, the label of each slide was uncovered.

Histological and immunohistochemical analyses

Masson's trichrome staining and immunohistochemistry were performed as previously described.\(^{23}\) The midshaft of the penis was immediately fixed in 4% paraformaldehyde overnight and then embedded in paraffin for further histologic studies. To assess fibrosis, Masson's trichrome staining was used to evaluate the smooth muscle-to-collagen ratio using images at ×200 magnification. Alpha smooth muscle actin (α-SMA; 1:50; Cell Signaling Technology, Danvers, MA, USA) was used to assess smooth muscle content at ×200 magnifications. For apoptosis, the tissue sections were incubated with antibody to caspase-3 (1:200; Cell Signaling Technology) at ×200 magnification. To assess oxidative stress, the tissue sections were incubated with antibodies to nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) (both 1:100; Cell Signaling Technology) at ×200 magnification. Ten sections of the corpus cavernosum were evaluated for each group, and six fields were counted for each section at ×200 magnification on a fluorescence microscope (Olympus, Tokyo, Japan) by an observer blinded to group allocation. Images were analyzed using Image-Pro Plus 4.5 software (Media Cybernetics, Silver Spring, MD, USA). The expression levels were standardized as a ratio to control.

Western blot and caspase-3 activity assay

The corpus cavernosum was homogenized in ice-cold radioimmune precipitation assay (RIPA) Lysis and Extraction Buffer (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. Western blot analysis was performed as previously described.\(^{24}\) After blocking in 5% nonfat milk in Tris-buffered saline Tween (TBST, 20 mmol l\(^{-1}\) Tris-HCl, pH 7.5;
150 mmol l−1 NaCl, 0.1% Tween 20) for 2 h at room temperature, the membranes were incubated overnight at 4°C with antibodies against Nrf2 (1:1000, Cell Signaling Technology), Kelch-like ECH associated protein 1 (Keap-1, 1:1000, Cell Signaling Technology), HO-1 (1:1000, Servicebio), TGF-β1 (1:500, Abcam, Cambridge, UK), B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax, 1:1000, Servicebio), Bcl-2 (1:1000, Servicebio), β-actin (1:5000, Cell Signaling Technology), Bcl-2-associated death promoter (Bad, 1:1000, Servicebio), phosphor-Bad (1:1000, Servicebio), the protein kinase B (AKT, 1:1000, Cell Signaling Technology), and phosphor-AKT (1:1000, Cell Signaling Technology). Then, the membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1:4000, Cell Signaling Technology) at room temperature for 90 min. After washing with TBST, immunoreactive bands were visualized with the GeneGnome gel imaging system (Syngene, Cambridge, UK). Densitometric analysis of the protein bands was performed with Image-Pro Plus software.

Caspase-3 activity in the penile tissue was quantified by a colorimetric enzyme-linked immunosorbent assay using a caspase-3 Activity Assay Kit (Beyotime, Shanghai, China) according to the manufacturer’s protocol. The relevant absorbance was measured at 405 nm with a microplate reader (Thermo Scientific, Waltham, MA, USA). The corresponding activity was calculated according to the standard curve and normalized by the protein concentration.

**Statistical analyses**

All data were shown as the mean ± standard deviation (s.d.), and differences among groups were analyzed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). Given the skewed distribution of data and the modest sample size, the nonparametric Kruskal–Wallis test and Mann–Whitney U test were used to assess statistical significance. *P* < 0.05 was considered statistically significant.

**RESULTS**

**Anatomy of CNs and ultrastructural changes**

The MPGs and CNs were identified dorsolateral to the prostate by blunt dissection and then stimulated with a bipolar hook electrode with parameters of 10 V at a frequency of 15 Hz with a square wave duration of 1.2 ms for 1 min (Figure 1). To validate the model of CN injury, TEM was used to identify the ultrastructural changes of CNs. Four weeks after nerve lesioning, disordered ultrastructure and damaged myelin sheath could be found in the BCNI group, compared with the Sham group (Figure 2a and 2b). In the group given bilateral cavernous neurectomy, both intact and damaged myelin sheaths were observed (Figure 2c). In other words, our model might be effective.

**Effect of daily losartan on erectile response**

ICP/MAP was widely used to evaluate erectile function. No significant differences (*P* = 0.7224) were found in baseline MAP among the four groups, and electrical stimulation of the CN induced a frequency-dependent increase in ICP in the other three experimental groups, except for the Neurectomy group. Four weeks postoperatively, the BCNI group had a significantly lower ICP/MAP ratio than the Sham group (*P* = 0.0211). However, the value was still lower than that in the Sham group (*P* < 0.01) (Figure 3). On the other hand, these results validated our model again.

**Effect of daily losartan on fibrosis in the corpus cavernosum**

Four weeks postoperatively, the ratio of smooth muscle to collagen detected by Masson’s trichrome staining was lower in the BCNI group and the Neurectomy group compared with the Sham group (both *P* < 0.01). After daily treatment with losartan, the ratio
Asian Journal of Andrology

The expression of TGF-β1 or immunophilin ligands, as reflected in clinical findings, the response to PDE5 inhibitors is poor in male patients with post-RP ED resulting from CN injury. Although attempts have been made to regenerate injured nerves by neurotrophic factors or immunophilin ligands,18,29 their responsiveness of...
Treatment with losartan in CNI-rats
Y Wang et al

Cavernous tissue would be compromised even if successful neural regeneration is achieved, due to the histologic changes in the target organ. Moreover, based on our experience, erectile function is unlikely to be restored after CVOD because of apoptosis and fibrosis. Hence, an early intervention to preserve the integrity of corpus cavernosum is likely critical for erectile functional recovery.

This study was aimed to identify the functional and morphological characterization of the corpus cavernosum after CN injury or neurectomy and then reveal whether early treatment with losartan would improve erectile function as well as its potential pathophysiologic mechanisms.

As for fibrosis, a previous study by Canguven et al. had fully demonstrated the antifibrotic mechanisms after bilateral CN injury and our outcomes merely reconfirmed its role. On the other hand, our model was also reconfirmed to be effective. Hence, this article mainly focused on the aspects of apoptosis and oxidative stress. A major finding of the current study was that Ang II increased apoptosis and oxidative stress in the corpus cavernosum, resulting in an impaired erectile response. Despite a modest effect on erectile function, the Ang II Type 1 receptor antagonist losartan could significantly reduce corporal apoptosis and oxidative stress via inhibiting the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 signaling pathways in the rat model of CN injury.

Ang II, produced and secreted by the human corpus cavernosum, was present in this tissue at a concentration about 200-fold higher than in plasma and played a key role in the pathogenesis of ED. A study by Kifor et al. showed that intracavernous injection of Ang II could terminate spontaneous erection, whereas treatment with losartan resulted in smooth muscle relaxation and erection in anesthetized dogs. In normotensive aged rats, losartan restored age-related ED attributable to increased oxidative stress and diminished endothelial nitric oxide synthase (eNOS) expression. In spontaneously hypertensive rats, long-term combined therapy with losartan and sildenafil was revealed as a useful tool for functional and structural modification in cavernous tissue. However, the definite role of Ang II in the case of CN injury was seldom involved. Hence, the Ang II Type 1 receptor antagonist losartan was chosen to discover its potential mechanisms in a rat model of CN injury.

Figure 5: Detection of apoptosis by TUNEL, cavernous caspase-3 immunohistochemical staining and western blot. (a) The TUNEL method; (b) bar graph of apoptotic index; (c) cavernous caspase-3 immunohistochemical staining; (d) bar graph of caspase-3 positive area; (e) western blot of the Akt/Bad/Bax/caspase-3 pathways; (f) bar graph of relative p-AKT/AKT expression; (g) bar graph of relative p-Bad/Bad expression; (h) bar graph of relative Bax/Bcl-2 expression; (i) bar graph of relative caspase-3 activity. Bar graph depicts caspase-3 activity in penile tissues measured by a Caspase-3 Activity Assay Kit, which was calculated according to a standard curve and normalized by the protein concentration. Data of western blot analysis and caspase-3 activity assay are shown as the fold changes over the control group. Bar graphs represent mean ± standard deviation. *P < 0.05 and **P < 0.01, the indicated group compared with the Sham group; #P < 0.05 and ##P < 0.01, the indicated group compared with the BCNI group. BCNI: bilateral cavernous nerve injury; TUNEL: terminal dextranucleotidyl transferase (TdT)-mediated dUTP nick end labeling; Bcl-2: B-cell lymphoma 2; Bax: Bcl-2-associated X protein; p-Bad: phosphor-Bad; AKT: the protein kinase B; p-AKT: phosphor-AKT.
The underlying pathogenic mechanisms in terms of CN injury-induced ED had not been fully understood. Canguven et al. revealed that Ang II induced activation of SMAD signaling by Ang II Type 1 receptors contributing to penile fibrosis after CN injury, whereas losartan treatment effectively restores erectile function through antifibrotic mechanisms. Cho et al. suggested that early inhibition of Rho-kinase after CN injury might restore erectile function and prevent corporal apoptosis, fibrosis, and CVOD by suppressing the Akt/Bad/Bax/caspase-3 and LIMK2/cofilin pathways. Through normalizing the LIMK2/Cofilin pathway, Park et al. showed that corporal fibrosis and erectile function could be improved by inhibition of LIMK2. Oxidative stress had also been implicated in the pathogenesis of ED, and Ang II was also reported to cause endothelial dysfunction by increasing reactive oxygen species levels. Further studies are required to identify key genes and signaling pathways. Advances in high-throughput sequencing methods and bioinformatics analysis should help in the identification of changes in gene expression in the rat model of CN injury.

Here, we found that daily treatment with losartan after CN injury only had a slight effect on erectile function, but it did significantly reduce corporal apoptosis and oxidative stress. Hence, an early administration of losartan might inhibit histopathologic changes in the corpus cavernosum. As presented in previous studies, the low efficacy of PDE5 inhibitors on the erectile response was strongly associated with its relatively small anti-apoptotic and anti-fibrotic effects, although it might improve erectile function via activation of the NO/cGMP pathway. Therefore, to enhance therapeutic effectiveness, combined therapy with losartan and PDE5 inhibitors had been recommended, and indeed, better performance had been shown in other models of ED. Along with the advances in technology and new therapeutic methods, numerous studies had focused on regenerating of the injured CN. However, because of the histologic changes, the compromised cavernous tissue limited the effectiveness of regenerative strategies. Based on our results, we hypothesized that combined therapy with losartan and these new therapeutic methods might produce better outcomes. Notably, losartan treatment should be started as soon as possible after injury.

In the case of diabetic rats with ED, primary study by Chen et al. found that angiotensin Type 1 receptor blocker could improve their erectile function. Therefore, they explored losartan in clinical treatment for diabetic patients suffering from ED. They found that losartan seemed to be effective and well-tolerated in diabetic ED patients, especially in mild-to-moderate cases, and meanwhile, combined losartan and tadalafil therapy appeared to be more effective than monotherapy. In this study, our results had indicated that an early administration of losartan could slightly restore erectile function and dramatically prevent corporal apoptosis and oxidative stress in the rat model of CN injury. In future studies, we would investigate the clinical effectiveness of losartan for postprostatectomy ED.

To the best of our knowledge, the present study comprehensively shed light on losartan reduced corporal apoptosis and oxidative stress following CN injury by suppressing the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 pathways. Although our results are of clinical importance,
several limitations should be noted. For example, combined therapy with losartan and PDE5 inhibitors was not used, and side effects were not examined. Our subsequent studies will focus on these issues. In addition, although we have revealed the role of apoptosis and oxidative stress in CN injury, there will be existence of other mechanisms remaining to be discovered. By means of high-throughput sequencing methods and bioinformatics analysis, we shall investigate more fully the genes and signaling pathways involved in CN injury-induced ED in future studies.

**CONCLUSIONS**

Taken together, our results shed light on that Ang II contributed to apoptosis and oxidative stress in the corpus cavernosum after CN injury, resulting in an impaired erectile response. Despite a modest effect on erectile function, the Ang II Type 1 receptor antagonist losartan significantly prevented corporal apoptosis and oxidative stress by inhibiting the Akt/Bad/Bax/caspase-3 and Nrf2/Keap-1 signaling pathways in the rat model of CN injury. Therefore, early administration of losartan might lessen histopathologic changes in the corpus cavernosum. Our novel findings helped advance our understanding of the pathophysiology and molecular mechanisms of CN injury-induced ED and also provided new insights for developing improved therapeutic strategies.

**AUTHOR CONTRIBUTIONS**

YW, XHM, and NHS designed the study, analyzed and interpreted the experimental data, and drafted and revised the manuscript. YW, XHM, and NHS carried out the studies and collected the experimental data. CC, YCW, XZ, and CJF performed the statistical analysis. NHS conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.

**COMPETING INTERESTS**

All authors declared no competing interests.

**ACKNOWLEDGMENTS**

This article was funded by the Medical key talent of Jiangsu Province (No. ZDRCA2016009), which had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in this study. We would like to thank the researchers and study participants for their contributions.

**REFERENCES**

1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013; 381: 163–65.
2. Ayta IA, Miclai JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–6.
3. Wang X, Liu C, Xu Y, Shen P, Shen Y, et al. Combination of mesenchymal stem cell injection with icarin for the treatment of diabetes-associated erectile dysfunction. PLoS One 2013; 12: e0174145.
4. Noldus J, Michl U, Graefen M, Haase A, Hammerer P, et al. Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. Eur Urol 2002; 42: 118.
5. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007; 178: 597–601.
6. Fode M, Ohi DA, Ralph D, Sonksen J. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int 2013; 112: 998–1008.
7. Weyne E, Castiglione F, Van der Aa F, Bivalacqua TJ, Albersen M. Landmarks in erectile function recovery after radical prostatectomy. Nat Rev Urol 2015; 12: 289–97.
8. Hu WL, Hu LQ, Song J, Li SW, Zheng XM, et al. Fibrosis of corpus cavernosum in animals following cavernous nerve ablation. Asian J Androl 2004; 6: 111–6.
9. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hu LQ, et al. Cavernous neurotrophism causes hyposia and fibrosis in rat corpus cavernosum. J Androl 2003; 24: 239–45.
10. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchard M, et al. Apoptosis in the rat penis after penile denervation. J Urol 1997; 158: 626–30.
11. Lagoda G, Jin L, Lefrerd TJ, Liu T, Burnett AL, FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Urol Sci 2007; 4: 908–16.
12. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Lucioni M, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotrophism in the rat. J Sex Med 2006; 3: 419–31.
13. Hu WL, Hu LQ, Li SW, Zheng XM, Tian BC. Expression of transforming growth factor-beta1 in penile tissue from rats with bilateral cavernosal nerve ablation. BJU Int 2004; 94: 424–8.
14. Weber MA. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med 2002; 3: 183–91.
15. Dauz VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift! Circulation 1994; 89: 493–8.
16. Kefi I, Williams GH, Vickers MA, Sullivan MP, Jobert P, et al. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–5.
17. Li WJ, Xu M, Gu M, Zheng DC, Gu J, et al. Losartan preserves erectile function by suppression of apoptosis and fibrosis of corpus cavernosum and corporal veno-occlusive dysfunction in diabetic rats. Cell Physiol Biochem 2017; 42: 333–45.
18. Zhang Y, Jia L, Zhang Y, Ji W, Li H. Angiotensin II silencing alleviates erectile dysfunction through down-regulating the RhoA/Rho kinase signaling pathway in rats with diabetes mellitus. Cell Physiol Biochem 2018; 45: 419–27.
19. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 2004; 171: 495–500.
20. Yuan Y, Li M, Wang T, Yang J, Rao K, et al. Taurine supplementation improves erectile function in rats with streptozotocin-induced type 1 diabetes via amelioration of penile fibrosis and endothelial dysfunction. J Sex Med 2016; 13: 778–85.
21. Li WJ, Zhou J, Li B, Wang H, Peng YB, et al. PARP inhibition restores erectile function by suppressing corporal smooth muscle apoptosis in diabetic rats. J Sex Med 2011; 8: 1072–82.
22. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14: 466–71.
23. Li WJ, Wang H, Zhou J, Li B, Zhang J, et al. P144, a TGFBeta1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats. J Sex Med 2013; 10: 2942–51.
24. Li H, Chen L, Wang T, Wang S, Liu J. The effect of cavernous nerve traction on erectile function in rats. PLoS One 2017; 12: e0186077.
25. Cho MC, Park K, Kim SW, Paik JS. Restoration of erectile function by suppression of corporal apoptosis, fibrosis and corporal veno-occlusive dysfunction with rho-kinase inhibitors in a rat model of cavernous nerve injury. J Urol 2015; 193: 1716–23.
26. Bella AJ, Fandel TM, Tantwongkhe K, Brant WQ, Klein RD, et al. Neurturin enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Brachial Plex Peripher Nerv Inj 2007; 2: 5.
27. Bakircioglu ME, Lin CS, Fan P, Sievert KD, Kan YW, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 2001; 165: 2103–9.
28. Hayashi N, Minor TX, Carrion R, Price R, Nunes L, et al. The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J Urol 2006; 176: 824–9.
29. Bella AJ, Hayashi N, Carrion RE, Price R, Lue TF. FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Sex Med 2007; 4: 341–6.
30. Jin HR, Chung YG, Kim WJ, Zhang LW, Piao S, et al. A mouse model of cavernous nerve injury-induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum. J Sex Med 2010; 7: 3351–64.
31. Ganguven O, Lagoda G, Sezen SF, Burnett AL. Losartan preserves erectile function after bilateral cavernous nerve injury via antiinfective mechanisms in male rats. J Urol 2009; 181: 2816–22.
32. Yang R, Yang B, Wen Y, Fang F, Cui S, et al. Losartan, an angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009; 6: 696–707.
33. Chen Y, Cui S, Lin H, Xu Z, Zhu W, et al. Losartan improves erectile function in diabetic patients: a clinical trial. J Int Impot Res 2012; 24: 217–20.
34. Park K, Shin JW, Oh JK, Ryu KS, Kim SW, et al. Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1. J Androl 2005; 26: 123–8.
35. Toblli JE, Cao G, Lombrana A, Rivero M. Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. J Sex Med 2007; 4: 1291–303.
36. Park J, Cho SY, Park K, Choi JS, Son H, et al. Role of inhibiting LIM-kinase2 in improving erectile function through suppression of corporal fibrosis in a rat model of cavernous nerve injury. Asian J Androl 2018; 20: 372–8.
37. Cui K, Tang Z, Li C, Wang T, Rao K, et al. Lipoxin A4 improves erectile dysfunction in rats with type I diabetes by inhibiting oxidative stress and corporal fibrosis. Asian
Silva FH, Monica FZ, Bau FR, Brugnerotto AF, Priviero FB, et al. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy. *J Sex Med* 2013; 10: 960–71.

Liu C, Cao Y, Ko TC, Chen M, Zhou X, et al. The changes of microRNA expression in the corpus cavernosum of a rat model with cavernous nerve injury. *J Sex Med* 2018; 15: 958–65.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©The Author(s) (2019)